Suppr超能文献

用于分离可溶性和不溶性亨廷顿蛋白物种的分级分离

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species.

作者信息

Ochaba Joseph, Morozko Eva L, O'Rourke Jacqueline G, Thompson Leslie M

机构信息

Department of Psychiatry and Human Behavior, University of California Irvine; UCI MIND, University of California Irvine.

UCI MIND, University of California Irvine; Department of Neurobiology and Behavior, University of California Irvine.

出版信息

J Vis Exp. 2018 Feb 27(132):57082. doi: 10.3791/57082.

Abstract

The accumulation of misfolded proteins is central to pathology in Huntington's disease (HD) and many other neurodegenerative disorders. Specifically, a key pathological feature of HD is the aberrant accumulation of mutant HTT (mHTT) protein into high molecular weight complexes and intracellular inclusion bodies composed of fragments and other proteins. Conventional methods to measure and understand the contributions of various forms of mHTT-containing aggregates include fluorescence microscopy, western blot analysis, and filter trap assays. However, most of these methods are conformation specific, and therefore may not resolve the full state of mHTT protein flux due to the complex nature of aggregate solubility and resolution. For the identification of aggregated mHTT and various modified forms and complexes, separation and solubilization of the cellular aggregates and fragments is mandatory. Here we describe a method to isolate and visualize soluble mHTT, monomers, oligomers, fragments, and an insoluble high molecular weight (HMW) accumulated mHTT species. HMW mHTT tracks with disease progression, corresponds with mouse behavior readouts, and has been beneficially modulated by certain therapeutic interventions. This approach can be used with mouse brain, peripheral tissues, and cell culture but may be adapted to other model systems or disease contexts.

摘要

错误折叠蛋白的积累是亨廷顿舞蹈病(HD)及许多其他神经退行性疾病病理学的核心。具体而言,HD的一个关键病理特征是突变型亨廷顿蛋白(mHTT)异常积累形成高分子量复合物以及由片段和其他蛋白质组成的细胞内包涵体。测量和理解各种形式含mHTT聚集体作用的传统方法包括荧光显微镜检查、蛋白质免疫印迹分析和滤膜捕获分析。然而,这些方法大多具有构象特异性,因此由于聚集体溶解性和分辨率的复杂性质,可能无法解析mHTT蛋白通量的完整状态。为了鉴定聚集的mHTT以及各种修饰形式和复合物,细胞聚集体和片段的分离与溶解是必不可少的。在此,我们描述一种分离并可视化可溶性mHTT、单体、寡聚体、片段以及一种不溶性高分子量(HMW)积累型mHTT物种的方法。HMW mHTT与疾病进展相关,与小鼠行为读数相符,并且已通过某些治疗干预得到有益调节。这种方法可用于小鼠脑、外周组织和细胞培养,但也可适用于其他模型系统或疾病背景。

相似文献

1
Fractionation for Resolution of Soluble and Insoluble Huntingtin Species.
J Vis Exp. 2018 Feb 27(132):57082. doi: 10.3791/57082.
2
Longitudinal Biochemical Assay Analysis of Mutant Huntingtin Exon 1 Protein in R6/2 Mice.
J Huntingtons Dis. 2018;7(4):321-335. doi: 10.3233/JHD-180329.
3
Meso scale discovery-based assays for the detection of aggregated huntingtin.
PLoS One. 2019 Mar 26;14(3):e0213521. doi: 10.1371/journal.pone.0213521. eCollection 2019.
4
Fragments of HdhQ150 mutant huntingtin form a soluble oligomer pool that declines with aggregate deposition upon aging.
PLoS One. 2012;7(9):e44457. doi: 10.1371/journal.pone.0044457. Epub 2012 Sep 12.
8
HIPK3 modulates autophagy and HTT protein levels in neuronal and mouse models of Huntington disease.
Autophagy. 2018;14(1):169-170. doi: 10.1080/15548627.2017.1393130. Epub 2018 Jan 29.

引用本文的文献

1
Biochemical analysis to study wild-type and polyglutamine-expanded ATXN3 species.
PLoS One. 2024 Dec 23;19(12):e0315868. doi: 10.1371/journal.pone.0315868. eCollection 2024.
2
Ferroptosis inducers enhanced cuproptosis induced by copper ionophores in primary liver cancer.
J Exp Clin Cancer Res. 2023 Jun 6;42(1):142. doi: 10.1186/s13046-023-02720-2.
4
A prion-like domain of TFEB mediates the co-aggregation of TFEB and mHTT.
Autophagy. 2023 Feb;19(2):544-550. doi: 10.1080/15548627.2022.2083857. Epub 2022 Jun 1.
5
Dynamics of huntingtin protein interactions in the striatum identifies candidate modifiers of Huntington disease.
Cell Syst. 2022 Apr 20;13(4):304-320.e5. doi: 10.1016/j.cels.2022.01.005. Epub 2022 Feb 10.
6
TBK1 phosphorylates mutant Huntingtin and suppresses its aggregation and toxicity in Huntington's disease models.
EMBO J. 2020 Sep 1;39(17):e104671. doi: 10.15252/embj.2020104671. Epub 2020 Aug 5.
7
Strategies to Investigate Ubiquitination in Huntington's Disease.
Front Chem. 2020 Jun 11;8:485. doi: 10.3389/fchem.2020.00485. eCollection 2020.
9
Global Proteome and Ubiquitinome Changes in the Soluble and Insoluble Fractions of Q175 Huntington Mice Brains.
Mol Cell Proteomics. 2019 Sep;18(9):1705-1720. doi: 10.1074/mcp.RA119.001486. Epub 2019 May 28.
10
Longitudinal Biochemical Assay Analysis of Mutant Huntingtin Exon 1 Protein in R6/2 Mice.
J Huntingtons Dis. 2018;7(4):321-335. doi: 10.3233/JHD-180329.

本文引用的文献

2
Mutant Huntingtin Disrupts the Nuclear Pore Complex.
Neuron. 2017 Apr 5;94(1):93-107.e6. doi: 10.1016/j.neuron.2017.03.023.
3
Human Neural Progenitor Transplantation Rescues Behavior and Reduces α-Synuclein in a Transgenic Model of Dementia with Lewy Bodies.
Stem Cells Transl Med. 2017 Jun;6(6):1477-1490. doi: 10.1002/sctm.16-0362. Epub 2017 Feb 22.
4
PIAS1 Regulates Mutant Huntingtin Accumulation and Huntington's Disease-Associated Phenotypes In Vivo.
Neuron. 2016 May 4;90(3):507-20. doi: 10.1016/j.neuron.2016.03.016. Epub 2016 Apr 14.
5
The emerging role of the first 17 amino acids of huntingtin in Huntington's disease.
Biomol Concepts. 2015 Mar;6(1):33-46. doi: 10.1515/bmc-2015-0001.
6
Therapeutic Approaches for Inhibition of Protein Aggregation in Huntington's Disease.
Exp Neurobiol. 2014 Mar;23(1):36-44. doi: 10.5607/en.2014.23.1.36. Epub 2014 Mar 27.
7
Aberrantly spliced HTT, a new player in Huntington's disease pathogenesis.
RNA Biol. 2013 Nov;10(11):1647-52. doi: 10.4161/rna.26706. Epub 2013 Oct 11.
9
SUMO-2 and PIAS1 modulate insoluble mutant huntingtin protein accumulation.
Cell Rep. 2013 Jul 25;4(2):362-75. doi: 10.1016/j.celrep.2013.06.034. Epub 2013 Jul 18.
10
TRiC's tricks inhibit huntingtin aggregation.
Elife. 2013 Jul 9;2:e00710. doi: 10.7554/eLife.00710.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验